Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera

British Journal of Haematology

Volumn 172, Issue 5, 2016, Pages 786-793

  Alvarez Larrán, Alberto ^a   Kerguelen, Ana ^b   Hernández Boluda, Juan C ^c   Pérez Encinas, Manuel ^d   Ferrer Marín, Francisca ^e   Bárez, Abelardo ^f   Martínez López, Joaquín ^g   Cuevas, Beatriz ^h   Mata, M Isabel ⁱ   García Gutiérrez, Valentín ^j   Aragües, Pilar ^k   Montesdeoca, Sara ^a   Burgaleta, Carmen ^l   Caballero, Gonzalo ^m   Hernández Rivas, J Angel ⁿ   Durán, M Antonia ^o   Gómez Casares, M Teresa ^p   Besses, Carles ^a  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d University Hospital of Santiago de Compostela   (Spain)

^e HOSPITAL MORALES MESEGUER   (Spain)

^f HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

ⁱ HOSPITAL COSTA DEL SOL   (Spain)

^j HOSPITAL RAMÓN Y CAJAL   (Spain)

^k HOSPITAL DE CRUCES   (Spain)

^l HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^m HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

ⁿ HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^o HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^p HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

more..

Author keywords

Hydroxycarbamide; Myeloproliferative neoplasms; Polycythaemia vera; Resistance intolerance; Response criteria

Indexed keywords

HYDROXYUREA; NUCLEIC ACID SYNTHESIS INHIBITOR;

ACUTE LEUKEMIA; ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD TOXICITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LEG ULCER; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RISK FACTOR; SKIN TOXICITY; SPLENOMEGALY; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG RESISTANCE; DRUG TOLERANCE; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; LEUKOPENIA; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; REGISTER; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG RESISTANCE; DRUG TOLERANCE; FEMALE; HUMANS; HYDROXYUREA; KAPLAN-MEIER ESTIMATE; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MIDDLE AGED; NUCLEIC ACID SYNTHESIS INHIBITORS; POLYCYTHEMIA VERA; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84958938143     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13886     Document Type: Article

References (18)

1. Alvarez-Larrán, A., Pereira, A., Cervantes, F., Arellano-Rodrigo, E., Hernández-Boluda, J.C., Ferrer-Marín, F., Angona, A., Gómez, M., Muiña, B., Guillén, H., Teruel, A., Bellosillo, B., Burgaleta, C., Vicente, V. & Besses, C. (2012) Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood, 119, 1363-1369.
2. Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Hehlmann, R., Hoffman, R., Kiladjian, J.J., Kröger, N., Mesa, R., McMullin, M.F., Pardanani, A., Passamonti, F., Vannucchi, A.M., Reiter, A., Silver, R.T., Verstovsek, S., Tefferi, A. & European LeukemiaNet. (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology, 29, 761-770.
3. Barosi, G., Birgegard, G., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Kiladjian, J.J., Lengfelder, E., McMullin, M.F., Passamonti, F., Reilly, J.T., Vannucchi, A.M. & Barbui, T. (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 113, 4829-4833.
4. Barosi, G., Birgegard, G., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H., Kiladijan, J.J., Lengfelder, E., Mesa, R., McMullin, M.F., Passamonti, F., Reilly, J.T., Vannucchi, A.M. & Barbu, T. (2010) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology, 148, 961-963.
5. Berk, P., Wasserman, L.R., Fruchtman, S. & Goldberg, J. (1995) Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. In: Polycythemia Vera and the Myeloproliferative Disorders (eds. by L.R. Wasserman, P.D. Berk & B.I. Berlin ), pp. 166-192. W.B Saunders company, Philadelphia.
6. Cervantes, F., Vannucchi, A.M., Kiladjian, J.J., Al-Ali, H.K., Sirulnik, A., Stalbovskaya, V., McQuitty, M., Hunter, D.S., Levy, R.S., Passamonti, F., Barbui, T., Barosi, G., Harrison, C.N., Knoops, L., Gisslinger, H. & COMFORT-II investigators. (2013) Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood, 122, 4047-4053.
7. Finazzi, G., Caruso, V., Marchioli, R., Capnist, G., Chisesi, T., Finelli, C., Gugliotta, L., Landolfi, R., Kutti, J., Gisslinger, H., Marilus, R., Patrono, C., Pogliani, E.M., Randi, M.L., Villegas, A., Tognoni, G., Barbui, T. & ECLAP Investigators. (2005) Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood, 105, 2664-2670.
8. Hernández-Boluda, J.C., Pereira, A., Cervantes, F., Alvarez-Larrán, A., Collado, M., Such, E., Arilla, M.J., Boqué, C., Xicoy, B., Maffioli, M., Bellosillo, B., Marugán, I., Amat, P., Besses, C. & Guillem, V. (2012) A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. Blood, 119, 5221-5228.
9. Kiladjian, J.J., Chevret, S., Dosquet, C., Chomienne, C. & Rain, J.D. (2011) Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. Journal of Clinical Oncology, 29, 3907-3913.
10. Landolfi, R., Di Gennaro, L., Barbui, T., De Stefano, V., Finazzi, G., Marfisi, R., Tognoni, G., Marchioli, R. & European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP). (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood, 109, 2446-2452.
11. Marchioli, R., Finazzi, G., Specchia, G., Cacciola, R., Cavazzina, R., Cilloni, D., De Stefano, V., Elli, E., Iurlo, A., Latagliata, R., Lunghi, F., Lunghi, M., Marfisi, R.M., Musto, P., Masciulli, A., Musolino, C., Cascavilla, N., Quarta, G., Randi, M.L., Rapezzi, D., Ruggeri, M., Rumi, E., Scortechini, A.R., Santini, S., Scarano, M., Siragusa, S., Spadea, A., Tieghi, A., Angelucci, E., Visani, G., Vannucchi, A.M., Barbui, T. & CYTO-PV Collaborative Group. (2013) Cardiovascular events and intensity of treatment in polycythemia vera. New England Journal of Medicine, 368, 22-33.
12. Najean, Y. & Rain, J.D. (1997) Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood, 90, 3370-3377.
13. Spivak, J.L. (2002) Polycythemia vera: myths, mechanisms, and management. Blood, 100, 4272-4290.
14. Tefferi, A. & Barbui, T. (2015) Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. American Journal of Hematology, 90, 162-173.
15. Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H.M., Barbui, T., Hanson, C.A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., Reilly, J.T., Gisslinger, H., Vannucchi, A.M., Cervantes, F., Finazzi, G., Hoffman, R., Gilliland, D.G., Bloomfield, C.D. & Vardiman, J.W. (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 110, 1092-1097.
16. Tefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A.M., Rodeghiero, F., Randi, M.L., Vaidya, R., Cazzola, M., Rambaldi, A., Gisslinger, B., Pieri, L., Ruggeri, M., Bertozzi, I., Sulai, N.H., Casetti, I., Carobbio, A., Jeryczynski, G., Larson, D.R., Müllauer, L., Pardanani, A., Thiele, J., Passamonti, F. & Barbui, T. (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia, 27, 1874-1881.
17. Vannucchi, A.M., Kiladjian, J.J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C.N., Pane, F., Zachee, P., Mesa, R., He, S., Jones, M.M., Garrett, W., Li, J., Pirron, U., Habr, D. & Verstovsek, S. (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New England Journal of Medicine, 372, 426-435.
18. Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., Catalano, J.V., Deininger, M.W., Miller, C.B., Silver, R.T., Talpaz, M., Winton, E.F., Harvey, J.H. Jr, Arcasoy, M.O., Hexner, E.O., Lyons, R.M., Raza, A., Vaddi, K., Sun, W., Peng, W., Sandor, V., Kantarjian, H. & COMFORT-I investigators. (2015) Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica, 100, 479-488.